BRAF V600E in PDAC (~1-3%, often in KRAS-WT subset). Tissue- agnostic dabrafenib + tramet...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRAF-V600E-PDAC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PDAC |
| Sources | SRC-CIVIC SRC-ESMO-PANCREATIC-2024 SRC-NCCN-PANCREATIC-2025 |
Actionability Facts
| Biomarker | BIO-BRAF-V600E |
|---|---|
| Variant | V600E |
| Disease | DIS-PDAC |
| ESCAT tier | IIIA |
| Recommended combinations | dabrafenib + trametinib (post-1L, tissue-agnostic) |
| Evidence summary | BRAF V600E in PDAC (~1-3%, often in KRAS-WT subset). Tissue- agnostic dabrafenib + trametinib (FDA 2022) approved for unresectable/metastatic V600E solid tumors after prior therapy. Consider after FOLFIRINOX failure in BRAF V600E PDAC. |
Notes
ESCAT IIIA. KRAS-WT PDAC subset enriched for actionable drivers (BRAF, NTRK, NRG1, FGFR2).
Used By
No reverse references found in the YAML corpus.